BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jul 12, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Victoza liraglutide: Extension study data

In a 26-week extension of an open-label, international Phase III trial in 658 patients inadequately controlled with metformin, 1.2 and 1.8 mg once-daily subcutaneous Victoza led to significantly greater reductions in HbA1c from baseline to 1 year vs. 100 mg once-daily Januvia sitagliptin (1.3% and 1.5%, respectively, vs. 0.9%, p<0.0001 for both). Additionally, a significantly greater proportion...

Read the full 273 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >